Quick context
Exenatide
模拟 GLP-1 信号，影响胰岛素、胰高血糖素、饱腹感和胃排空。
Approved uses exist, but dose, formulation, device and monitoring are product- and indication-specific. A community table cannot replace the prescribing information or a prescription.
Back to all 64 profiles
Approved medicine特定用途获批
Community protocol · Exenatide
Exenatide: community information and evidence, clearly separated.
A complete substance profile covering documented community themes, scientific context and explicit safety boundaries. Missing or non-standardised data are not replaced with estimates.
Also known as: Exendin-4 analogue · Byetta · Bydureon
Sources checked: 27 August 2026
重要安全与责任声明
本页记录并评估网络社区信息，不构成医疗或治疗建议、个体咨询，也不是使用邀请。
No medical, therapeutic or individual recommendation. Information is provided without warranty and used at your own risk. No liability for calculation errors, use, contamination, interactions or consequences.
Amounts, timing and cycles
Approved medicine
Approved uses exist, but dose, formulation, device and monitoring are product- and indication-specific. A community table cannot replace the prescribing information or a prescription.
Amount status
Only the prescribing information for the exact approved product applies; brands, concentrations and indications are not interchangeable.
Profile evidence level: established.
Timing
Intervals, time of day and missed-dose handling depend on the product and indication.
No individual recommendation.
Cycle/duration
Approved medicines are clinician-managed treatment, not freely designed community cycles.
No individual recommendation.
No matching detail page found in the reference source
The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.
复配与 U-100 换算
No generic calculator
For approved finished products, only the relevant prescribing information, original concentration and intended delivery system apply. Prefilled pens, syringes or product-specific vials must not be converted with a generic U-100 table.
For approved finished products, only the relevant prescribing information, original concentration and intended delivery system apply. Prefilled pens, syringes or product-specific vials must not be converted with a generic U-100 table.
Mechanism and research questions
GLP-1 receptor agonist
Exenatide is classified as “GLP-1 receptor agonist”. 模拟 GLP-1 信号，影响胰岛素、胰高血糖素、饱腹感和胃排空。 This describes the investigated pathway but does not validate a community use, amount, route or combination.
GLP-1受体激活
研究人员研究激活GLP-1受体如何影响餐后的饱腹感、胃排空和胰岛素释放。他们通常测量血糖曲线、体重和一段时间内的进食量,类似于观察一个人吃完饭后多久会再次感到饥饿。
血糖与食欲结果
研究人员研究某物质如何在一天中改变血糖水平和饥饿感,类似于观察不同餐食后一个人的饱腹感。常见测量指标包括血糖读数以及关于饥饿感和进食量的问卷。
胃排空
这项研究考察食物离开胃部进入肠道的速度,这一过程影响进食后的饱腹感。排空速度通常通过影像学或呼气测试来测量,类似于测算一餐食物通过消化系统所需的时间。
What communities discuss
These themes describe discussion and vendor claims. They do not prove benefit, safety, product identity or suitable use.
体重管理论坛
在这些论坛中,用户比较不同产品之间自己的体重变化、副作用以及感知到的食欲变化。经常会分享前后对比照片和个人时间线。这类轶事和商家营销宣传并不是科学的疗效证明。
综合健康论坛
人们在此交流使用各类产品后情绪、睡眠和整体感受等更宽泛的健康印象,通常没有结构化的记录。这类笼统印象无法替代有针对性的临床检查。
来源与纯度讨论
人们讨论哪些商家被认为更值得信赖,以及不同批次之间纯度检测结果的差异。这类社区评估基于有限的样本,无法替代对每一批次进行的独立实验室检测。
Adverse effects and risk boundaries
- 根据靶点，可能出现胃肠道反应、脱水以及血糖或食欲变化；肠促胰素类药物还可能涉及胆囊、胰腺和视网膜病变警示。
- Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
- A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.
Exclusion groups and professional assessment
- 妊娠、严重胃排空障碍以及相关胰腺、胆囊、肾脏或内分泌疾病均需专业评估；具体说明书还可能列出其他禁忌。
- Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
- Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.
Monitoring and laboratory markers
- 根据物质和适应证，可评估体重、血压、水合状态、血糖/HbA1c、肝肾指标及合并用药；其他检查由症状决定。
- Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.
Evidence boundary
证据充分
该批准基于对照试验;较新的药物显示出略有不同的效果特征。
Published evidence
所述生物学作用已有充分依据,或针对明确产品和用途已有经监管机构审查的大量人体数据。这些结论不能自动套用于其他产品或用途。
艾塞那肽源自毒蜥唾液中的艾塞那肽-4,其结构与基于人体序列的GLP-1类似物不同。
Storage and stability
- The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
- Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
- Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.
Troubleshooting and error sources
- U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
- Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
- Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
- Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.
Regulatory status and WADA
特定用途获批
在至少一个司法辖区作为特定适应证的处方活性成分；本网站不提供该产品。
WADA 2026
The atlas has no explicit WADA flag for this profile. That does not automatically mean every form, route or related class is permitted in sport.
WADA — 2026 Prohibited ListComparisons and related profiles
Combinations / stacks
- Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
- Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
- Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.
Frequently asked questions
Is an amount shown here a recommendation?
No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.
Does the U-100 calculator prove correct use?
No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.
Can this profile be combined with other substances?
Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.
Which source controls when information conflicts?
For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.
Are community claims clinical evidence?
No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.
Sources and evidence layers
Primary sources and official registries take priority. The community reference is labelled separately.
- Primary/technical sourceFDA: GLP-1 receptor agonists
- Primary/technical sourceDailyMed — BYETTA prescribing information
- Primary/technical sourceDailyMed — BYDUREON BCISE prescribing information